ASCO 2022 Conference Coverage


 

ASCO 2022 A Phase 1b/2 Study of the BET Inhibitor ZEN-3694 in Combination With Talazoparib for Treatment of Patients With TNBC Without gBRCA1/2 Mutations

27 views
July 26, 2022
0 Comments
Login to view comments. Click here to Login
Breast